Beovu

Active Ingredient(s): Brolucizumab-dbll
FDA Approved: * October 7, 2019
Pharm Company: * NOVARTIS PHARMS CORP
Category: Vision / Eye Health

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Beovu Overview

Brolucizumab (INN) is a humanized single-chain antibody fragment designed for the treatment of wet age-related macular degeneration.[1][2] This drug was developed by ESBATech (discovery to phase 2a), Alcon Laboratories (phase 2b) and Novartis (phase 3). Laboratory development names are RTH258 (Novartis Compound Code) and ESBA1008 (ESBATech AG). Brolucizumab successfully completed phase 3 development in wet age-related macular degeneration (AMD) meeting the prim...

Read more Beovu Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brolucizumab

Recent Beovu Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Beovu: (1 result)

Sorted by National Drug Code

• 0078-0827 Beovu 6 mg/.05ml Intravitreal Injection, Solution by Novartis Pharmaceuticals Corporation

Other drugs which contain Brolucizumab-dbll or a similar ingredient: (1 result)

• BROLUCIZUMAB